Exelixis
EXEL
#2109
Rank
HK$58.74 B
Marketcap
HK$205.95
Share price
-1.53%
Change (1 day)
22.40%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024HK$8.96 M38.21%
2023HK$6.48 M-41.81%
2022HK$11.14 M-31.9%
2021HK$16.36 M-20.71%
2020HK$20.64 M303.63%
2019HK$5.11 M-70.5%
2018HK$17.33 M8.82%
2017HK$15.92 M-17.35%
2016HK$19.27 M-75.68%
2015HK$79.23 M19.37%
2014HK$66.37 M258.49%
2013HK$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
HK$22.53 MHK$43.31 M๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$3.41 MHK$70.14 M๐Ÿ‡ซ๐Ÿ‡ท France
HK$39.92 MHK$95.81 M๐Ÿ‡บ๐Ÿ‡ธ USA
HK$36.47 MHK$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$87.32 MHK$0.26 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$90.55 MHK$0.28 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.24 BHK$0.50 B๐Ÿ‡บ๐Ÿ‡ธ USA
N/AHK$0.06 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AHK$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA